Charles River Laboratories International (NYSE:CRL) Sets New 12-Month Low - Here's What Happened

Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) reached a new 52-week low during trading on Monday . The stock traded as low as $128.03 and last traded at $130.10, with a volume of 124148 shares traded. The stock had previously closed at $136.90.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of recent analyst reports. The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a report on Friday, December 13th. Finally, UBS Group reaffirmed a "neutral" rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $182.00.

Remove Ads

Charles River Laboratories International Trading Down 0.4 %

The firm has a fifty day moving average of $156.71 and a 200-day moving average of $177.01. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market capitalization of $4.89 billion, a price-to-earnings ratio of 663.71, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.46 earnings per share. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Several institutional investors have recently added to or reduced their stakes in the stock. Rothschild Investment LLC increased its position in shares of Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares during the last quarter. Versant Capital Management Inc grew its stake in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares in the last quarter. Optiver Holding B.V. bought a new position in Charles River Laboratories International during the 4th quarter worth approximately $37,000. Finally, GeoWealth Management LLC grew its position in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after acquiring an additional 190 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).